PASITHEA THERAPEUTICS ANNOUNCES ACTIVATION OF CLINICAL TRIAL SITE AT UNIVERSITY OF ALABAMA AT BIRMINGHAM FOR ONGOING PHASE 1/1B TRIAL OF PAS-004 IN ADULT NF1 PATIENTS

Reuters · 11/04 12:03

Please log in to view news
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.